- Home
- EDSA vs RDHL Comparison
EDSA vs RDHL Comparison
Compare EDSA & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- RDHL
- Stock Information
- Founded
- EDSA 2015
- RDHL 2009
- Country
- EDSA Canada
- RDHL Israel
- Employees
- EDSA N/A
- RDHL N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- RDHL Health Care
- Exchange
- EDSA Nasdaq
- RDHL Nasdaq
- Market Cap
- EDSA 6.2M
- RDHL 6.8M
- IPO Year
- EDSA N/A
- RDHL N/A
- Fundamental
- Price
- EDSA $2.45
- RDHL $2.45
- Analyst Decision
- EDSA Strong Buy
- RDHL
- Analyst Count
- EDSA 1
- RDHL 0
- Target Price
- EDSA $21.00
- RDHL N/A
- AVG Volume (30 Days)
- EDSA 32.2K
- RDHL 121.9K
- Earning Date
- EDSA 05-09-2025
- RDHL 04-11-2025
- Dividend Yield
- EDSA N/A
- RDHL N/A
- EPS Growth
- EDSA N/A
- RDHL N/A
- EPS
- EDSA N/A
- RDHL N/A
- Revenue
- EDSA N/A
- RDHL $3,707,000.00
- Revenue This Year
- EDSA N/A
- RDHL $224.90
- Revenue Next Year
- EDSA N/A
- RDHL $82.69
- P/E Ratio
- EDSA N/A
- RDHL N/A
- Revenue Growth
- EDSA N/A
- RDHL N/A
- 52 Week Low
- EDSA $1.55
- RDHL $2.40
- 52 Week High
- EDSA $5.59
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- EDSA 53.34
- RDHL 26.68
- Support Level
- EDSA $2.31
- RDHL $2.64
- Resistance Level
- EDSA $2.55
- RDHL $2.90
- Average True Range (ATR)
- EDSA 0.12
- RDHL 0.23
- MACD
- EDSA -0.02
- RDHL 0.07
- Stochastic Oscillator
- EDSA 48.28
- RDHL 6.76
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.